Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials

Data from 2 MPN clinical trials (the phase 2 MPN-RC 111 study of pegylated interferon alfa-2a among those with hydroxyurea resistance or intolerance, and the phase 3 MPN-RC 112 study of pegylated interferon alfa-2a versus hydroxyurea in treatment-naïve patients with high-risk ET or PV) suggest that clinicians should factor in symptom burden when evaluating treatment efficacy and tolerability for patients with PV and ET.